Addressing the Treatment Gap in Ischemic Stroke

Episode Summary

Executive Summary: The episode explores Basking Biosciences’ effort to transform acute ischemic stroke care with BB31, a first-in-class reversible thrombolytic that targets von Willebrand factor (VWF). CEO Julia Owens and CSO Shahid Nimji argue that current stroke therapies help too few patients because of narrow time windows, access barriers, and irreversible bleeding risk. Their VWF-based approach, paired with a reversal agent (BB25), aims to widen treatment access and improve safety.

Main Topics: Limitations of current stroke standard of care (Priority: 5/5): Existing therapies—fibrinolytics and mechanical thrombectomy—treat only a minority of ischemic stroke patients because of short treatment windows, need for specialized centers, and bleeding concerns. Bleeding risk and reversibility in clinician decision-making (Priority: 5/5): The speakers emphasize that irreversible intracranial hemorrhage is the major barrier to broader thrombolytic use and shapes how cautiously clinicians treat stroke patients. Why von Willebrand factor is the therapeutic target (Priority: 5/5): Basking argues VWF is central to clot formation and is present in clots across time points, making it a promising target for acute stroke intervention and potentially related thrombotic biology. BB31 mechanism and acute-stroke fit (Priority: 5/5): BB31 is described as an RNA aptamer that rapidly binds VWF, with fast onset and a short duration suited to acute treatment and potential use up to 24 hours after stroke onset. BB25 reversal agent and safety strategy (Priority: 4/5): BB25 is designed to rapidly neutralize BB31 via complementary base pairing, giving clinicians control to stop the drug’s effect if bleeding occurs or risk increases. Development status, financing, and broader indications (Priority: 3/5): The company is in Phase 2B for stroke, has completed a $55 million financing, and is exploring additional thrombotic indications while prioritizing stroke as the largest unmet need.

Key Arguments: Most ischemic stroke patients receive no acute treatment today because current options are constrained by time, geography, and risk. Thrombolytics have a narrow 3–4.5 hour window and significant bleeding risk, so fewer than 10% of patients receive them. Mechanical thrombectomy can help out to 24 hours but requires a specialized center and is only beneficial for certain occlusion types. Irreversible bleeding risk makes clinicians reluctant to use fibrinolysis, since hemorrhage after treatment can be fatal and difficult to reverse. VWF is central to clot architecture and is found in every studied clot sample from thrombectomy patients, supporting it as a broad target. BB31’s short half-life and rapid onset make it suitable for an emergency setting where temporary clot disruption is desired. A reversible thrombolytic could expand treatment to patients with unknown onset, anticoagulant use, older age, or fragile vasculature. BB25 adds a layer of physician control that could materially change risk tolerance and increase use of thrombolytics. Stroke is both a major unmet medical need and a potentially large commercial market, making it the company’s initial focus.

Data Points: Stroke prevalence: 1 in 4 people - Used to describe how common stroke is over a lifetime Ischemic stroke share of all strokes: 85% - The interview focuses on ischemic stroke, the clot-caused subtype Patients receiving acute treatment: Greater than 80% receive no acute treatment - Current therapies reach only a small minority of patients Use of fibrinolytic drugs: Less than 10% of patients - Despite being available for about 30 years, few eligible patients receive them Fibrinolytic time window: Around 3 to 4.5 hours - Window from stroke onset for thrombolytic treatment Thrombectomy time window: Up to 24 hours - Mechanical clot removal may still help later than drugs Bleeding mortality after fibrinolysis: 40% of patients who bleed die - Discussed as a consequence of non-reversible hemorrhage Hemorrhage risk cited by clinician: Up to 3% chance of killing the patient - Rationale for some clinicians avoiding fibrinolytics BB31 onset of action: Within 5 minutes - Rapid onset supports acute stroke use BB31 duration of effect: 10 to 12 hours - At clinically studied doses, matching acute treatment needs BB31 development stage: Phase 2B - Company is currently recruiting for the stroke trial BB31 treatment window being studied: Up to 24 hours - Reflects the company’s goal to widen eligibility beyond current drugs Funding raised: $55 million - Financing led by ARCH to support development Runway from prior financing: Into the second half of next year - Management says the company remains well capitalized

Pivotal Quotes: "If you can put into the physician's hand control of a drug such that any deleterious effect, such as something as significant as intracranial hemorrhage, can be turned off ... that would be game-changing." — Julia Owens: On how reversibility could change thrombolytic use in stroke "There was VWF central to clot composition and, in fact, was a component of every clot studied in these patient populations." — Shahid Nimji: Explaining why von Willebrand factor is the therapeutic target "Time equals brain." — Julia Owens: On why faster and more accessible treatment options are needed

Implications: If BB31 and BB25 perform as hoped, acute stroke care could become faster, safer, and more accessible beyond major stroke centers, potentially treating far more patients and reshaping emergency thrombotic therapy.